MIPS Molecular Imaging Program at Stanford
Center for Cancer Nanotechnology Excellence Focused on Therapy Response


Anna Wu, Ph.D.Anna Wu, Ph.D.
Project Leader: Project 5
Professor, Molecular & Medical Pharmacology
Associate Director, Crump Institute for Molecular Imaging
Crump Institute for Molecular Imaging
David Geffen School of Medicine at UCLA
700 Westwood Plaza, A342B
PO Box 951770
Los Angeles, CA 90095-1770

Phone: (310) 794-5088
Fax: (310) 206-8975

Email: awu@mednet.ucla.edu
Website: http://www.crump.ucla.edu

Project Leader: Project 5, Professor of Molecular and Medical Pharmacology (UCLA)
Dr. Wu, Professor in the Dept. of Molecular and Medical Pharmacology at UCLA School of Medicine, is Associate Director of the Crump Institute for Molecular Imaging at UCLA. She serves as Co-Director of the NCI-funded UCLA Scholars in Oncologic Molecular Imaging (SOMI) postdoctoral training program, and is Co-Director of the Tumor Immunology Program in the UCLA Jonnson Comprehensive Cancer Center. Dr. Wu is also an Adjunct Professor, Molecular Biology, Beckman Research Institute of the City of Hope, Duarte, CA. She is a past member of the California Breast Cancer Research Council (2000-2003) serving as Council Chair during the final year of her term. Her affilitations as an investigator in the UCLA SPORE in Prostate Cancer and the City of Hope Lymphoma SPORE bring key expertise to the CCNE-TR team in the area of antibody-directed in vivo tumor targeting. Dr. Wu's research interests focus on molecular approaches to detection and treatment of cancer. In particular her work centers on understanding and using molecular recognition (e.g. using antibodies or peptides) to distinguish tumor cells from normal cells. Her group has used genetic engineering of anti-tumor antibodies to optimize their use for targeted delivery of radionuclides for radioimmunotherapy and radioimmunoscintigraphy. In addition to reducing immunogenicity (through generation of chimeric, humanized, and human antibodies), her group has pioneered the systematic engineering and evaluation of the pharmacokinetics and tumor targeting of recombinant antibody fragments. She has established (with Dr. Gambhir) the utility of engineered antibodies for microPET imaging in a variety of preclinical tumor system (including colorectal, breast, prostate and lymphoma xenograft models), and participated in the translation of one of the fragments (anti-CEA minibody) into a clinical imaging study. She has also collaborated with Drs. Gambhir and Weiss on the modification of quantum dots for in vivo tumor targeting.

Footer Links: